Gratus Capital’s Cantel Medical Corporation CMD Stock Holding History

Gratus Capital’s Portfolio CMD Stock Details CMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,940	Closed	-$232K	–	201
2020 Q4	$232K	Buy	+2,940	New	+$172K	0.03%	165

Other funds holding CMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LGP

Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Diker Management New York $112M AUM 59.78% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Gratus Capital's CMD Position: Q1 2021 in Review

Gratus Capital sold out of Cantel Medical Corporation (CMD) in Q1 2021, closing a stake of 2,940 shares — an estimated $232K sold.

Gratus Capital first reported a position in CMD in Q4 2020 and held it in 1 quarter. The position peaked at $232K in Q4 2020. 234 funds tracked by Wall St. Rank hold CMD as of Q1 2021.

Gratus Capital reported no remaining Cantel Medical Corporation position as of Q1 2021 after selling out during the quarter.
Gratus Capital sold 2,940 Cantel Medical Corporation shares in Q1 2021, an estimated $232K.
Gratus Capital first reported a position in Cantel Medical Corporation in Q4 2020 and held it in 1 quarter.
Gratus Capital's Cantel Medical Corporation position peaked at $232K in Q4 2020.
234 funds tracked by Wall St. Rank held Cantel Medical Corporation as of Q1 2021.

Based on Gratus Capital's 13F filing for Q1 2021, filed 4 May 2021.